CJC-1295 not working? 9 real reasons and fixes

Last updated 2026-07-30

Why does CJC-1295 seem to not be working at all?

Most of the time it's not that the molecule failed, it's that something in the handling, timing, or expectation-setting broke down before the peptide ever got a fair shot. CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue. It binds the GHRH receptor on pituitary somatotrophs and stimulates pulsatile GH release, it does not dump a fixed amount of GH into your blood the way an injection of GH itself would ^[1]. That mechanism matters because it means the response depends heavily on how much releasable GH your pituitary has sitting around, what your GHRH receptors are doing, and whether the rest of your GH axis (sleep, insulin, body fat) is cooperating. The original modified GRF(1-29) research, including the drug affinity complex (DAC) version studied by Teichman and colleagues, showed CJC-1295 with DAC raised mean plasma GH levels and IGF-1 levels in healthy adults over multi-week dosing, with IGF-1 increases sustained for up to 6 days after a single dose in some analyses and continuing through weeks of repeated dosing ^[2]. That is a real, published pharmacodynamic effect. It is not the same as a guarantee that any individual user, especially one self-administering an unregulated product bought online, will see a visible or subjective change on a similar timeline. So when people say 'CJC-1295 isn't working,' they're almost always talking about one of three failure points: the product itself (degraded, underdosed, or mislabeled), the protocol (wrong timing, wrong frequency, wrong duration), or the expectation (looking for gym-bro transformation in two weeks when the actual data describes IGF-1 and GH pulse changes measured in a lab). We'll go through each.

Did you reconstitute or store it wrong?

This is the single most common practical reason CJC-1295 underperforms, and it has nothing to do with biology. CJC-1295 ships as a lyophilized (freeze-dried) powder that has to be reconstituted with bacteriostatic water or sterile water before injection. Get this step wrong and you can destroy or waste most of the peptide before it's even in the syringe. Peptide chemistry basics apply here the same way they do to other lyophilized compounds: manufacturer guidance for peptide handling consistently emphasizes keeping vials refrigerated (roughly 2-8°C / 36-46°F) once mixed, protecting from light, and avoiding vigorous shaking, which can shear and denature the peptide chain ^[3]. Swirl gently, don't shake. Room-temperature storage of reconstituted peptide for days at a time, or repeated freeze-thaw cycles, degrades potency well before the labeled expiration. A few checks worth running before you assume the peptide is 'not working': - Was the vial kept refrigerated after mixing, not left on a counter or in a gym bag?

• Was it mixed with the correct diluent volume for your intended concentration, or eyeballed?
• Has it been more than 20-30 days since reconstitution? Most compounded peptide guidance treats reconstituted peptides as time-limited once mixed, even refrigerated.
• Was the powder itself clumped, discolored, or slow to dissolve? That can indicate prior heat exposure in shipping. If you can't answer these confidently, the product is the first suspect, not the mechanism.

Are you using CJC-1295 with DAC or without DAC, and does it matter?

It matters a lot, and mixing up the two is a frequent cause of disappointing results. 'CJC-1295' is used loosely online to mean two chemically different things. CJC-1295 with DAC (drug affinity complex) has a maleimide group attached that binds covalently to albumin in the blood, extending its half-life to roughly 6-8 days according to the original pharmacokinetic studies, which is why DAC dosing protocols in the clinical research were built around once- or twice-weekly injections ^[2]. CJC-1295 without DAC (often sold or discussed as 'Mod GRF 1-29' or 'CJC-1295 no-DAC') lacks that albumin-binding tail and has a half-life closer to 30 minutes, meaning it needs multiple daily injections timed around GH pulses (usually before bed and/or before meals) to have a comparable effect ^[4]. | Feature | CJC-1295 with DAC | CJC-1295 no-DAC (Mod GRF 1-29) |

Are you injecting at the wrong time relative to food and sleep?

Timing is not a minor detail with a GHRH analogue, it's close to the whole game. GH secretion is naturally pulsatile and peaks overnight during slow-wave sleep, and it's suppressed by elevated blood glucose and insulin ^[5]. If you inject CJC-1295 right after a carbohydrate-heavy meal, you're asking the pituitary to release GH into a hormonal environment that's actively working against it. Most protocols derived from the pharmacology (not from any single dosing trial, since there isn't one definitive published human dosing schedule for self-administered use) call for injecting on an empty stomach, commonly 20-30 minutes before bed and/or first thing in the morning, with at least 2-3 hours since the last meal. Eating soon after injection is generally considered lower-impact than eating right before, since the GH pulse itself happens fairly quickly, but a large insulin spike at the wrong moment can still blunt it. Sleep quality itself is the bigger lever most people ignore. If you're getting 5 broken hours a night, no peptide protocol is going to compensate for the loss of the deep-sleep GH pulse that CJC-1295 is trying to amplify. This is one of the more folklore-heavy corners of the topic: bodybuilding forums will tell you exact minute windows for injection timing with total confidence, but that precision comes from anecdote, not from a controlled trial measuring outcomes at different injection times. The directionally correct advice (fasted, near sleep, low insulin) is grounded in known GH physiology; the down-to-the-minute versions are not.

Is your dose actually too low (or is the product underdosed)?

Two separate problems hide under this question: you might be dosing correctly for a product that's mislabeled, or you might genuinely be underdosing a legitimate product. The published Teichman study used CJC-1295 with DAC at doses in the range of 30-60 mcg/kg in some analyses and fixed doses used in other GHRH-analogue pharmacokinetic work, administered by the research team under controlled conditions with laboratory-confirmed blood levels ^[2]. Self-administered protocols circulating online for no-DAC CJC-1295 commonly describe doses in the 1-2 mcg/kg range per injection, multiple times daily, but this figure comes from compounding-community convention, not from a dose-ranging trial designed to find a minimum effective self-administered dose. That gap between 'studied under clinical conditions' and 'typical unsupervised protocol' is real, and nobody has published data closing it cleanly. A separate and more mundane issue: peptide products sold outside a regulated pharmacy chain have shown, in independent testing surveys, meaningful lot-to-lot variability in actual peptide content versus label claims. The FDA has issued warnings specifically about compounded and research-use peptides sold without proper oversight, noting concerns about purity, sterility, and accurate labeling ^[6]. If your source can't produce a certificate of analysis for the specific lot you received, you have no way to know if you're underdosing, overdosing, or injecting something else entirely. This is exactly why route matters: working through a provider who reviews the product and a pharmacy that fulfills it against a real specification removes the biggest source of dosing uncertainty. CJC-1295 Co's provider-reviewed model exists for this reason, connecting people to a fulfilling pharmacy partner rather than an unverified vial from a message board link.

Could your age or existing GH/IGF-1 status be limiting the response?

GHRH analogues work by stimulating your own pituitary, and that gland's responsiveness changes with age and baseline hormone status. Natural GH secretion declines steadily after young adulthood, a well-documented process sometimes called somatopause, with substantial drops in pulsatile GH output by midlife ^[7]. A GHRH analogue can amplify the pulses that are still available to be triggered, but it cannot manufacture pituitary reserve that isn't there. This has a practical implication that's rarely stated plainly in marketing copy: a 50-year-old with age-typical GH decline is working from a lower baseline and may see a smaller relative bump in IGF-1 than a 28-year-old with a fully intact axis, even on an identical protocol. The original CJC-1295 DAC study population skewed toward healthy but not elderly adults ^[2], so extrapolating the size of the effect to an older, more GH-deficient population is a guess, not a documented result. Pre-existing conditions matter too. People with diagnosed adult growth hormone deficiency, pituitary damage, or prior head trauma affecting the hypothalamic-pituitary axis may have blunted or absent GHRH-receptor responsiveness altogether, in which case no amount of CJC-1295 will produce the expected GH pulse, because the receiving end of the signal isn't intact. If you have a known pituitary or hypothalamic condition, this is a conversation for an endocrinologist, not a peptide protocol adjustment.

Why isn't the ipamorelin combination doing more?

CJC-1295 is very often paired with ipamorelin, and the rationale is mechanistic, not proven-in-outcome. Ipamorelin is a ghrelin-receptor agonist (a GH secretagogue in the same family as GHRP-2 and GHRP-6, though more selective) that triggers GH release through a different receptor than CJC-1295's GHRH-receptor pathway ^[8]. Combining a GHRH analogue with a ghrelin-mimetic is a rational stacking idea because the two pathways are additive in animal and early human pharmacology, pulsatile GHRH signaling plus ghrelin-receptor stimulation produces a larger GH pulse than either alone in several published secretagogue studies ^[8][9]. That said, 'the mechanisms are additive in a lab' is a different claim from 'the combination reliably produces better body composition or clinical outcomes in self-administered users,' and no large trial has tested CJC-1295 plus ipamorelin against either agent alone for the outcomes people actually care about (strength, fat loss, sleep quality, recovery). If your combined protocol isn't producing a bigger effect than CJC-1295 alone did, the likely culprits are the same ones covered above (dosing, timing, product quality) rather than the pairing logic itself being wrong. It's also worth separating expectation from mechanism here: adding a second peptide doesn't fix a reconstitution error or a bad injection schedule, it just adds a second variable to troubleshoot. For a broader read on what a realistic combined protocol looks like over weeks and months, see cjc-1295 results timeline.

How long does CJC-1295 actually take to show results, and are you quitting too early?

Impatience is a real, underrated reason people conclude 'it's not working.' The IGF-1 elevations documented in the DAC pharmacokinetic studies were measured across multiple weeks of dosing, with sustained IGF-1 increases described through the study duration (commonly reported in the 6-week range in follow-on protocols referencing this data), not after a handful of injections ^[2]. Subjective changes like sleep quality or recovery, to the extent they occur, would plausibly lag behind the measurable IGF-1 shift, and visible body composition change lags further still behind that. A rough, honest framework based on how the GH/IGF-1 axis is known to behave: expect at least 3-4 weeks before you'd have any lab basis (an IGF-1 blood test) for saying the peptide is doing anything measurable, and treat anything under that window as too early to judge. Cosmetic or performance changes that people attribute to CJC-1295 in self-reports typically show up, if at all, in the 8-12 week range, well past the point most impatient users have already quit or switched products. None of this is from a trial measuring self-reported outcomes on a timeline, it's inference from the known kinetics of IGF-1 response plus basic physiology of how long body composition change takes under any intervention. If you want the fuller picture of what a realistic month-by-month expectation looks like, cjc-1295 before and after and cjc-1295 results timeline both cover the pacing question in more depth.

Could an injection technique or site problem be blocking absorption?

Subcutaneous injection technique is easy to get sloppy about, and small errors reduce how much peptide actually reaches circulation. Injecting into scar tissue, repeatedly using the exact same tiny spot until it's inflamed or lipohypertrophic, or injecting too shallow (intradermal instead of subcutaneous) can all reduce absorption. Basic technique that most self-injection guidance agrees on: rotate sites (abdomen, thigh, that kind of spacing), pinch a fold of skin, use a fresh needle each time (dull needles bruise tissue and can affect absorption and comfort), and let alcohol dry before injecting since injecting through wet alcohol can sting and, more relevantly, doesn't affect absorption but is a sign of rushed technique that often correlates with other rushed steps like measuring dose or reconstitution volume. None of this is exotic. It's the same technique guidance used for any subcutaneous self-injected medication, and it's worth an honest look if everything else in your protocol checks out and results still aren't showing.

Is it possible CJC-1295 was never going to do what you expected?

This is the least comfortable reason, and probably the most common one when everything else checks out. A lot of the specific outcome claims attached to CJC-1295 online (rapid fat loss, dramatic muscle gain, skin tightening, joint repair) trace back to bodybuilding forum posts and marketing copy, not to the published pharmacology. What the actual research supports is narrower: increased GH pulse amplitude and sustained IGF-1 elevation over weeks of dosing in the studied population ^[2]. Whether that translates into a specific person's visible body composition change depends on diet, training, sleep, age, and baseline GH status, variables the original studies didn't isolate for that purpose because they weren't designed to measure gym-outcome endpoints. If your protocol, timing, storage, and product quality are all reasonable and you still don't feel a difference, it's worth asking honestly whether the expectation was ever supported by evidence or whether it came from a forum thread describing someone else's stack, diet, training age, and (unverifiable) product quality all at once. For a level-headed comparison of what's actually documented versus what's assumed, cjc-1295 pros and cons and is cjc-1295 worth it both separate the two directly. And if you're trying to figure out whether your experience is typical or an outlier, cjc-1295 success rate covers how variable self-reported outcomes actually are.

What should you check first if CJC-1295 stops working after it initially seemed to?

A protocol that worked for a few weeks and then plateaued is a different problem than one that never worked, and it points toward different causes. The most likely explanations, in rough order of how often they come up: the reconstituted vial degraded past its usable window (see the storage section above), your body's IGF-1 response reached a new steady state and further dose increases without a break aren't adding much (some secretagogue protocols build in cycling, off-weeks, for this reason, though the evidence for cycling improving outcomes versus continuous dosing is thin), or something else changed, less sleep, more stress, a new medication affecting insulin or cortisol, that's now working against the mechanism. Getting an IGF-1 blood test at the point where you first felt it working, and again at the point it seemed to stop, is the only way to know whether the biology actually changed or whether it's a subjective plateau. Most people never do this, which means most 'it stopped working' reports are impossible to verify one way or the other.

Frequently asked questions

Why does CJC-1295 sometimes seem to do nothing at all?

The most common causes are practical, not biological: improper reconstitution or storage, wrong timing relative to meals and sleep, an underdosed or mislabeled product, or judging results before the 3-4 week window needed to see any measurable IGF-1 change. Age and baseline GH status also cap the response, since the peptide amplifies existing pituitary output rather than creating GH independently ^[2][7].

How long before CJC-1295 should be showing results?

Published pharmacokinetic data on CJC-1295 with DAC shows sustained IGF-1 elevation measured across multiple weeks of dosing ^[2]. A reasonable, evidence-based expectation is no measurable lab change (IGF-1 blood test) before 3-4 weeks, and no visible or subjective change reliably before 8-12 weeks, if it happens at all for a given individual.

Does the DAC vs no-DAC difference actually change results?

Yes. CJC-1295 with DAC has a half-life of roughly 6-8 days and is typically dosed once or twice weekly, producing a flatter, sustained GH/IGF-1 elevation ^[2]. No-DAC CJC-1295 has a half-life near 30 minutes and needs multiple daily injections to approximate a pulsatile effect ^[4]. Using the wrong dosing frequency for the version you have is a common cause of disappointing results.

Can bad storage or reconstitution ruin CJC-1295?

Yes, and this is one of the most common reasons people report no effect. Reconstituted peptide should generally stay refrigerated (roughly 2-8°C), be mixed gently without vigorous shaking, and be used within the timeframe specified by the source, often 20-30 days ^[3]. Room-temperature storage or repeated freeze-thaw cycles can meaningfully degrade potency before that window even ends.

Is CJC-1295 supposed to be injected on an empty stomach?

Most protocols recommend injecting fasted, commonly before bed and/or in the morning, because elevated blood glucose and insulin suppress GH secretion ^[5]. This guidance is grounded in known GH physiology, but the exact minute-by-minute timing windows popular on forums are anecdotal convention, not results from a controlled timing trial.

Why would CJC-1295 plus ipamorelin not work better than CJC-1295 alone?

The two act on different receptors (GHRH receptor for CJC-1295, ghrelin receptor for ipamorelin), and combining them is mechanistically additive in published secretagogue pharmacology ^[8][9]. But no large trial has tested the combination against either agent alone for real-world outcomes, so a lack of extra effect is more often explained by dosing, timing, or product-quality issues than by the pairing logic being wrong.

Can age make CJC-1295 less effective?

Yes. Natural pulsatile GH secretion declines substantially with age, a process called somatopause ^[7]. CJC-1295 amplifies existing GHRH-driven pituitary pulses rather than manufacturing new GH capacity, so someone with more age-related decline may see a smaller relative response than a younger person with an intact GH axis, even on an identical protocol.

Could my source's product just be underdosed or fake?

It's a real possibility. The FDA has warned specifically about purity, sterility, and labeling accuracy concerns with compounded and research-use peptides sold outside regulated pharmacy channels ^[6]. Without a certificate of analysis for your specific lot, there's no way to confirm the vial contains the labeled amount of active peptide.

Does injection technique affect whether CJC-1295 works?

It can. Injecting too shallow, reusing inflamed or scarred sites, or using dull needles can reduce subcutaneous absorption. Rotating injection sites and using correct subcutaneous technique each time is basic but often overlooked, especially by people troubleshooting a protocol that seems to have stopped working.

Is it normal for CJC-1295 to stop working after a few weeks?

A plateau after initial response usually points to a different cause than never working at all: a degraded vial past its usable window, a new steady state in IGF-1 that a dose increase alone won't move much further, or a lifestyle change (less sleep, more stress) working against the mechanism. An IGF-1 blood test at both points is the only reliable way to confirm what actually changed.

Do I need a blood test to know if CJC-1295 is working?

It's the only objective check available to a self-administered user. An IGF-1 blood test before starting and again at 4-6 weeks shows whether the GHRH pathway is actually being stimulated, independent of subjective feelings about sleep, recovery, or appearance, which are much slower and harder to attribute to one variable.

Is most of what I read online about CJC-1295 dosing actually studied?

No, and this is worth being honest about. The core pharmacokinetic data (half-life, IGF-1 elevation) comes from a small number of published studies on CJC-1295 with DAC ^[2]. Most specific self-administered dosing schedules, timing windows, and combination protocols circulating on forums are community convention, not results from controlled dosing trials.

Sources

1. NIH StatPearls, Growth Hormone Physiology: GHRH stimulates pulsatile GH release from pituitary somatotrophs
2. Teichman et al., Journal of Clinical Endocrinology & Metabolism (2006): CJC-1295 with DAC raises GH and sustains IGF-1 elevation over weeks of dosing
3. NIH, Peptide storage and stability handling guidance: Reconstituted peptides require refrigeration and gentle handling to preserve potency
4. NCBI Bookshelf, Growth hormone releasing hormone analogues pharmacokinetics: Non-DAC GHRH analogue fragments have short half-lives requiring frequent dosing
5. NIH StatPearls, Physiology of Growth Hormone Secretion: GH secretion peaks during slow-wave sleep and is suppressed by elevated glucose and insulin
6. U.S. Food and Drug Administration, compounding risk communications: FDA has raised concerns about purity, sterility, and labeling of compounded peptide products
7. NIH StatPearls, Growth Hormone Deficiency and Aging: Pulsatile GH secretion declines substantially with age (somatopause)
8. NCBI, Ipamorelin ghrelin receptor agonist pharmacology review: Ipamorelin acts on the ghrelin receptor, a distinct pathway from GHRH receptor agonists
9. NIH StatPearls, Growth Hormone Secretagogues: Combining GHRH pathway and ghrelin receptor pathway stimulation produces additive GH release in published pharmacology